# A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS

> **NCT05569746** · PHASE2 · COMPLETED · sponsor: **Inmunova S.A.** · enrollment: 57 (actual)

## Conditions studied

- Diarrhea-Associated Hemolytic Uremic Syndrome
- Pediatric Kidney Disease
- Hemolytic-Uremic Syndrome

## Interventions

- **DRUG:** INM004
- **OTHER:** SoC

## Key facts

- **NCT ID:** NCT05569746
- **Lead sponsor:** Inmunova S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-06
- **Primary completion:** 2023-05-15
- **Final completion:** 2023-07-14
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05569746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05569746, "A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05569746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*